Aspira Pathlab promoter Jay Arvind Bhanushali acquires 74 shares
- Promoter Jay Arvind Bhanushali acquired 74 equity shares in Aspira Pathlab via open market on September 10, 2026
- The acquisition leaves his total stake unchanged at 7.25% of the voting capital
- His total holding increased from 7,46,377 to 7,46,451 shares
- The disclosure was filed with the BSE on September 11, 2026, under SEBI SAST Regulations
*this image is generated using AI for illustrative purposes only.
Aspira Pathlab promoter Jay Arvind Bhanushali acquired 74 equity shares in the company through the open market on September 10, 2026. The transaction was disclosed to the BSE on September 11, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
The acquisition represents a negligible change in his overall stake. Bhanushali held 7,46,377 shares, constituting 7.25% of the total voting capital, prior to this transaction. Following the purchase, his total holding stands at 7,46,451 shares, maintaining the same 7.25% stake.
What the Numbers Show
The acquisition of 74 shares is immaterial relative to Bhanushali's existing position of over 7.4 lakh shares. The transaction does not alter the promoter's voting power or control structure within Aspira Pathlab & Diagnostics Ltd.
Transaction Details
| Metric | Value |
|---|---|
| Acquirer | Jay Arvind Bhanushali |
| Shares Acquired | 74 |
| Mode | Open Market |
| Date of Acquisition | September 10, 2026 |
| Stake Before | 7.25% (7,46,377 shares) |
| Stake After | 7.25% (7,46,451 shares) |
The company’s total equity share capital remains at ₹10,29,30,000, divided into 1,02,93,000 equity shares of ₹10 each. There were no encumbrances, warrants, or convertible securities involved in this transaction.
Historical Stock Returns for Aspira Pathlab
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.47% | +2.15% | -9.35% | +67.79% | +46.45% | 0.0% |
Could this small-scale open market purchase signal the beginning of a larger accumulation strategy by the promoter in the coming quarters?
How might Aspira Pathlab's upcoming financial results influence the promoter's confidence and future shareholding decisions?
Are there any pending regulatory filings or insider trading patterns from other key promoters that provide context to this isolated transaction?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
